Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06648671 Pharmacodynamics in Healthy Subjects
NCT02407353Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06648671 in Alzheimer's disease (AD) (4 arms), sponsored by Pfizer. Primary endpoint: CSF Aβ40 and Aβ42 concentration at maximum change from baseline. Started Oct 2015; status: completed.
02
Drugs
PF-06648671
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02407353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407353.